

MEDICAID PREFERRED DRUG LIST

Health and Human Services Interim Committee

June 17, 2015

9:00 a.m. — 11:45 a.m.

1. Introduction and overview
 - Chair McIff and Rep. Ward
2. Prior authorization process
Patient/provider satisfaction
 - Mr. Michael Hales (*Deputy Director, Utah Department Of Health*)
3. Pharmacy and Therapeutics Committee
 - Professor Karen M. Gunning (*Pharm. D.; Clinical professor, University School of Medicine; Former co-chair of the Utah Department of Health's Pharmacy and Therapeutics Committee*)
 - Mr. Hales
4. Utah Medicaid's pharmacy experience
 - Mr. Hales
5. Pharmaceutical manufacturers
 - PhRMA (*Invited*)
6. Psychiatry community
 - Ms. Michelle McOmbler (*CEO, Utah Medical Association*)
 - Dr. Anne G. Lin, M.D. (*Assistant Professor, University of Utah School of Medicine; President, Utah Psychiatric Association*)
7. PEHP's experience with mental health drugs on a PDL
 - Mr. Chet Loftis (*Director, Public Employees Health Program*)
8. Mental health PDLs in other states
 - Mr. Mark Andrews, (*Committee policy analyst*)
9. Select Health's Experience with mental health drugs on PDLs
 - Dr. Eric Cannon (*Pharm. D.; Assistant Vice-President of Pharmacy Benefits for SelectHealth*)
10. Local mental health providers
 - Rep. Ward — Review of Letter from Mr. Kyle Snow (*CEO, Northeastern Counseling Center, and Chairman of UAC's Utah Behavioral Healthcare Committee*)

11. Potential uses of any savings for Utah's public mental health system
 - Mr. Doug Thomas (*LCSW; Director, Utah Division of Substance Abuse and Mental Health*)
12. Potential modifications to rules or statutes
 - Rep. Ward (and others)
13. Wrap-up
 - Chair McIff

Source: Office of Legislative Research and General Counsel, 6/17/15

